Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

scientific article

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/01.QAI.0000185313.48933.2C
P8608Fatcat IDrelease_cwrp6j6rcrb3ljboncslgn4czu
P698PubMed publication ID16280695

P50authorJulio MontanerQ1712378
Joep LangeQ6214187
Bonaventura Clotet SalaQ20100355
Jean-François DelfraissyQ27882675
Christine KatlamaQ47006550
Keikawus ArastéhQ47158286
Hans-Jürgen StellbrinkQ47158312
Adriano LazzarinQ56447702
Sharon WalmsleyQ72252101
Joseph J EronQ87874621
Daniel KuritzkesQ88453812
David J. CooperQ107702551
Claude DrobnesQ125271277
Lynn SmileyQ125271521
Calvin CohenQ125271533
P2093author name stringMark Nelson
Jacques Reynes
Keith Henry
Jacob Lalezari
Ralph Demasi
Benoit Trottier
Denise Guimaraes
Jain Chung
Miklos P Salgo
Mary O'Hearn
Fiona Hughes
Anne Bertasso
Tosca Kinchelow
Christopher Natale
Anna Shikhman
Peter Piliero
Silvia Bader-Weder
Laurence Bourdeau
Belinda Atkins
Emily Labriola-Tompkins
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectanti-retroviral agentQ50430310
P304page(s)413-421
P577publication date2005-12-01
P1433published inJournal of Acquired Immune Deficiency SyndromesQ6294722
P1476titleSafety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
P478volume40